Back

National Association for Continuing Education

  • Lung Diseases, Interstitial
  • Rheumatic Diseases

Modern Management of ILDs: Risk, Screening, and Treatment

Interstitial lung diseases (ILDs) present an escalating clinical burden for which delayed intervention compromises patient outcomes. Early warning signs, such as interstitial lung abnormalities, progress to overt ILD in approximately 10% of patients annually but are routinely overlooked. This systemic disconnect is particularly devastating within high-risk populations, such as patients with systemic autoimmune rheumatic diseases (SARDs). Real-world data expose alarming screening gaps, often delaying life-saving evaluation until irreversible functional decline has occurred. Despite advanced antifibrotic therapies and updated management guidelines, many clinicians lack the confidence to interpret progression criteria or navigate complex treatment pathways, delaying therapy initiation. Because lost lung function is rarely recoverable, the traditional “wait and see” approach is no longer tenable. Join a leading ILD expert as he describes evidence-based strategies to optimize patient trajectories, including, risk stratification, screening protocols, and guideline-concordant treatment plans utilizing recent clinical data on antifibrotic therapies.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1.25 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 1.25 credits
  • Commercial Support
  • Released
    Jun 10, 2026
  • Last day to claim credit
    Jun 11, 2027 8 months left